In HaCaT keratinocytes, 250 nM CDDO-Me produced a broader transcriptional response than 10 µM PRL-295 after 14 h. In a separate migration assay with proliferation suppressed, CDDO-Me impaired gap closure relative to vehicle. These findings limit generalizations about selectivity or wound repair across models. [2]
KEAP1 C151 dependence of NQO1 induction in fibroblasts
Cell-based study · Stable male wild-type and Keap1-C151S murine embryonic fibroblasts [1]
CDDO-Me increased Nqo1 transcript and NQO1 activity in wild-type MEFs, with no induction in C151S MEFs under the tested conditions. Alternative inducers retained activity in mutant cells; basal NQO1 differed between genotypes.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1, 3, 10 and 30 nM for qPCR; 1 and 30 nM for enzyme activity
- Exposure duration
- 24 h for qPCR; 48 h for enzyme activity
- Method
- Cell treatment followed by beta-actin-normalized qPCR or protein-normalized lysate NQO1 activity assay
- Vehicle
- DMSO control; final DMSO fraction not specified in the selected methods
- Co-treatment
- No combined drug treatment. Separate 15Δ-PGJ2 (10 µM) and CdCl2 (30 µM) controls tested residual mutant responsiveness.
- Reported limits
- No EC50 or IC50 established. Three independent experiments per assay; numerical SD values not tabulated in the selected evidence.
Methods and source locations
Compound reported in the paper: Bardoxolone methyl; Compound label in the paper: CDDO-Me
Applies to the paper-reported methyl ester and stated model/conditions; no salt conversion, stereochemical re-analysis, or catalog lot validation.
Fig. 1B-G and caption; Results: CDDO-Me Induces Gene Expression and Enzyme Activity of NQO1; Materials, Cell Culture, RNA Preparations from Cells, NQO1 Enzyme Activity
Nqo1 mRNA relative to genotype-matched vehicle: qPCR normalized to beta-actin; genotype-specific vehicle set to 1; n = 3 independent experiments, mean ± SD; one-way ANOVA — Fig. 1B caption and labels; RNA Preparations from Cells
NQO1 enzymatic activity relative to genotype-matched vehicle: Protein-normalized lysate activity; vehicle set to 1 within genotype; n = 3 independent experiments, mean ± SD; ANOVA followed by Dunnett test — Fig. 1G and caption; NQO1 Enzyme Activity
CDDO-Me impaired keratinocyte gap closure under migration-assay conditions
Cell-based study · Human immortalized HaCaT keratinocytes; silicone-mold gap assay with mitomycin-C pretreatment to suppress proliferation [2]
At 250 nM, CDDO-Me impaired gap closure compared with 1% DMSO vehicle over the reported 72 h assay, increasing residual gap area and integrated wound burden. This is an in-vitro migration result, not an animal wound-healing result.
Literature-Reported Treatment Conditions
- Treatment concentration
- 250 nM CDDO-Me
- Exposure duration
- 0–72 h, imaged every 24 h
- Method
- Silicone-mold gap closure; ImageJ gap-area analysis after mitomycin-C pretreatment
- Vehicle
- 1% DMSO in medium; treatment solutions adjusted to equal DMSO content
- Co-treatment
- Mitomycin-C pretreatment (1 µg/mL for 1 h), followed by washing before CDDO-Me; separate ADJ-310 and PRL-295 comparator groups at 10 µM.
- Reported limits
- No exact gap-area means or AUC values are inferred from bars. Culture methods list DMEM or DermaLife K for migration without assigning one to the plotted experiment.
Methods and source locations
Compound reported in the paper: Bardoxolone methyl; Compound label in the paper: CDDO-Me
Applies to the paper-reported methyl ester and stated model/conditions; no salt conversion, stereochemical re-analysis, or catalog lot validation.
Fig. 4B-E and caption; Results Sec3 migration paragraph; Methods Cell migration, HaCaT cell culture, Preparation of treatment solutions, Image analysis and Statistical analysis
Residual gap area and total normalized gap-area AUC: n = 8; mean ± SD; ImageJ; one-way ANOVA for AUC with Benjamini, Krieger and Yekutieli FDR correction. Time-course and time-point panels are from the same experiment. — Fig. 4B-D and caption; Cell migration; Statistical analysis
Broader keratinocyte transcriptional response to CDDO-Me than PRL-295
Cell-based study · HaCaT human keratinocytes; DMSO control, 250 nM CDDO-Me and 10 µM PRL-295 groups [2]
CDDO-Me increased expression of NRF2-associated genes while producing more differentially expressed genes than PRL-295 at the tested, unequal concentrations. The comparison does not establish direct binding to additional targets or NRF2 independence.
Literature-Reported Treatment Conditions
- Treatment concentration
- 250 nM CDDO-Me; separate 10 µM PRL-295 comparator
- Exposure duration
- 14 h
- Method
- RNA sequencing using Illumina NovaSeq 6000; differential expression versus DMSO
- Vehicle
- DMSO in medium; shared preparation methods specify equalized 1% DMSO
- Reported limits
- No matched-exposure or equipotent comparison; no NRF2-null arm in this experiment. Pathway-enrichment graphics are not adopted.
Methods and source locations
Compound reported in the paper: Bardoxolone methyl; Compound label in the paper: CDDO-Me
Applies to the paper-reported methyl ester and stated model/conditions; no salt conversion, stereochemical re-analysis, or catalog lot validation.
Fig. 6A-E (first original figure image), caption; Results Sec5 first three paragraphs; Methods mRNA sequencing and Preparation of treatment solutions
Genes differentially expressed versus DMSO: n = 3 per group; DESeq2 adjusted P < 0.05 using Benjamini-Hochberg FDR correction; counts checked in Fig. 6C-D, gene labels in Fig. 6E — Fig. 6C-E; Sec5; mRNA sequencing methods